Coherus Aiming For More Than 10% Slice Of US Adalimumab Market
US-Based Firm Has December 2021 FDA Goal Date
Coherus believes its customer-focused approach will stand it in good stead for the multi-billion-dollar adalimumab market • Source: Shutterstock 
